A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disease with heterogenous
pathophysiological changes that develop years before the onset of clinical symptoms. These …
pathophysiological changes that develop years before the onset of clinical symptoms. These …
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease
Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease
RJ Perrin, R Craig-Schapiro, JP Malone, AR Shah… - PloS one, 2011 - journals.plos.org
Background Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied
during the 'preclinical'stage (pathology present with cognition intact) before severe neuronal …
during the 'preclinical'stage (pathology present with cognition intact) before severe neuronal …
CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels
Abstract Development of disease-modifying therapies against Alzheimer's disease (AD)
requires biomarkers reflecting the diverse pathological pathways specific for AD. We …
requires biomarkers reflecting the diverse pathological pathways specific for AD. We …
Alzheimer disease pathology and the cerebrospinal fluid proteome
Background Altered proteome profiles have been reported in both postmortem brain tissues
and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with …
and body fluids of subjects with Alzheimer disease (AD), but their broad relationships with …
Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: a literature review
KEJ Wesenhagen, CE Teunissen… - Critical reviews in …, 2020 - Taylor & Francis
Alzheimer's disease (AD) is the most common cause of dementia and is characterized by
aggregation of amyloid and tau proteins in the brain. Results from genetic studies suggest …
aggregation of amyloid and tau proteins in the brain. Results from genetic studies suggest …
High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer's disease in human cerebrospinal fluid
RC Hendrickson, AYH Lee, Q Song, A Liaw, M Wiener… - PloS one, 2015 - journals.plos.org
Disease modifying treatments for Alzheimer's disease (AD) constitute a major goal in
medicine. Current trends suggest that biomarkers reflective of AD neuropathology and …
medicine. Current trends suggest that biomarkers reflective of AD neuropathology and …
Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome
Robust and accessible biomarkers that can capture the heterogeneity of Alzheimer's
disease and its diverse pathological processes are urgently needed. Here, we undertook an …
disease and its diverse pathological processes are urgently needed. Here, we undertook an …
Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease
Introduction Alzheimer's disease (AD) is the most common cause of dementia, characterized
by progressive cognitive decline. Protein biomarkers of AD brain pathology, including β …
by progressive cognitive decline. Protein biomarkers of AD brain pathology, including β …
A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's …
Alzheimer's disease (AD) is the most common cause of dementia. Biomarkers are required
to identify individuals in the preclinical phase, explain phenotypic diversity, measure …
to identify individuals in the preclinical phase, explain phenotypic diversity, measure …